From July 10 to 13, the International Industrial Exhibition INNOPROM – 2023 was held in Ekaterinburg; the Medsintez Plant presented its products at the joint booth of the Ministry of Industry and Trade of the Russian Federation. As part of the main topic of the exhibition, “Sustainable Production: Strategies for Renewal,” the company demonstrated its readiness to launch Russia’s first production of recombinant drugs, which are currently produced in Russia only by the Medsintez Plant. This year, representatives of the Russian Government headed by Mikhail Mishustin, Prime Minister of the Russian Federation, and heads of foreign delegations visited the exhibition. The delegates got acquainted with the advanced developments of leading Russian enterprises.

On June 27, 2023, the signing ceremony of the Memorandum of Understanding between Central Pharmaceutical Company CPC1, JSC and Medsintez Plant LLC was held at the headquarters of Central Pharmaceutical Company CPC1, JSC in Hanoi. The ceremony was attended by representatives of the management of CPC1, the Medsintez Plant, Pharmviet JSC and the Embassy of the Russian Federation in Vietnam.

This year marks 20 years since the nationally renowned Medsintez Plant in the Urals began manufacturing its first preparations. Today it is a modern full-cycle biotechnological enterprise that develops and manufactures pharmaceutical substances and drugs that meet international GMP and ISO standards. There are few pharmaceutical companies in the country that manufacture products meeting such high requirements. Thus, according to the Ministry of Industry and Trade of the Russian Federation, as of January 1, 2021, there were only 271 enterprises in Russia with a certificate of compliance with GMP standards.

 

Novouralsk celebrates the 20th anniversary of Medsintez Plant LLC, a Russian manufacturer of insulin, the antiviral drug Triazavirin, preparations for IVF treatment, and other medicines. Federal Press reports on how the Sverdlovsk company makes Russian patients independent of supplies from abroad, what challenges it is facing now and what new products it plans to bring to the market.

From May 23 to 26, 2023, the 10th (29th) National Congress of Endocrinologists with international participation Personalized Medicine and Practical Healthcare organized by the Russian Association of Endocrinologists and and the Federal State Budgetary Institution National Medical Research Center for Endocrinology of the Ministry of Health of Russia was held in Moscow. Among the leading domestic and foreign pharmaceutical manufacturers the Medsintez Plant as usual presented its main products at the booth – preparations of genetically engineered and analogue human insulin Rosinsulin.